BNP Paribas Asset Management
ARQT icon

BNP Paribas Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

BNP Paribas Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.6K Sell
2,046
-11,228
-85% -$262K ﹤0.01% 1747
2026
Q1 		$313K Buy
13,274
+6,462
+95% +$165K ﹤0.01% 1306
2025
Q4 		$198K Buy
6,812
+5,727
+528% +$147K ﹤0.01% 1336
2025
Q3 		$20K Buy
1,085
+39
+4% +$615 ﹤0.01% 1379
2025
Q2 		$15K Buy
+1,046
New +$14.7K ﹤0.01% 1610

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BNP Paribas Asset Management's ARQT Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Arcutis Biotherapeutics (ARQT) stake by 85% in Q2 2026, selling an estimated $262K and leaving 2,046 shares worth $53.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1747.

BNP Paribas Asset Management first reported a position in ARQT in Q2 2025 and has held it in 5 quarters since. The position peaked at $313K in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • BNP Paribas Asset Management held 2,046 shares of Arcutis Biotherapeutics worth $53.6K as of Q2 2026.
  • BNP Paribas Asset Management sold 11,228 Arcutis Biotherapeutics shares in Q2 2026, an estimated $262K.
  • Arcutis Biotherapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1747 holding.
  • BNP Paribas Asset Management first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Arcutis Biotherapeutics position peaked at $313K in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.